tiprankstipranks
Merrimack Pharmaceuticals Announces Nasdaq Delisting and Liquidation Plan
Company Announcements

Merrimack Pharmaceuticals Announces Nasdaq Delisting and Liquidation Plan

Merrimack Pharmaceuticals Inc. (MACK) just unveiled an announcement.

On April 30, 2024, a company outlined its plan to voluntarily delist and deregister its Common Stock from Nasdaq, projecting an initial liquidating cash dividend between $14.92 and $15.15 per share, with the exact amount pending stockholder approval. Key dates for the dissolution process include a stop trading date on May 15, 2024, and an anticipated payment date of May 17, 2024. This strategic move follows the filing of a definitive proxy statement regarding the company’s impending liquidation and dissolution, emphasizing the importance of stockholders reviewing this material before voting.

Find detailed analytics on MACK stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyBiotech Alert: Searches spiking for these stocks today
TipRanks Auto-Generated NewsdeskMerrimack Pharmaceuticals Approves Liquidation and Dividend
TipRanks Auto-Generated NewsdeskMerrimack Pharmaceuticals Plans Liquidating Dividend
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!